基于WGCNA的结直肠癌预后预测RBP基因标记的开发和验证。

IF 2.7 3区 生物学
Lu Cao, Lili Duan, Rui Zhang, Wanli Yang, Ning Yang, Wenzhe Huang, Xuemin Chen, Nan Wang, Liaoran Niu, Wei Zhou, Junfeng Chen, Yiding Li, Yujie Zhang, Jinqiang Liu, Daiming Fan, Hong Liu
{"title":"基于WGCNA的结直肠癌预后预测RBP基因标记的开发和验证。","authors":"Lu Cao,&nbsp;Lili Duan,&nbsp;Rui Zhang,&nbsp;Wanli Yang,&nbsp;Ning Yang,&nbsp;Wenzhe Huang,&nbsp;Xuemin Chen,&nbsp;Nan Wang,&nbsp;Liaoran Niu,&nbsp;Wei Zhou,&nbsp;Junfeng Chen,&nbsp;Yiding Li,&nbsp;Yujie Zhang,&nbsp;Jinqiang Liu,&nbsp;Daiming Fan,&nbsp;Hong Liu","doi":"10.1186/s41065-023-00274-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>RNA binding proteins (RBPs) have been implicated in oncogenesis and progression in various cancers. However, the potential value of RBPs as prognostic indicators and therapeutic targets in colorectal cancer (CRC) requires further investigation.</p><p><strong>Methods: </strong>Four thousand eighty two RBPs were collected from literature. The weighted gene co-expression network analysis (WGCNA) was performed to identify prognosis-related RBP gene modules based on the data attained from the TCGA cohorts. LASSO algorithm was conducted to establish a prognostic risk model, and the validity of the proposed model was confirmed by an independent GEO dataset. Functional enrichment analysis was performed to reveal the potential biological functions and pathways of the signature and to estimate tumor immune infiltration. Potential therapeutic compounds were inferred utilizing CMap database. Expressions of hub genes were further verified through the Human Protein Atlas (HPA) database and RT-qPCR.</p><p><strong>Results: </strong>One thousand seven hundred thirty four RBPs were differently expressed in CRC samples and 4 gene modules remarkably linked to the prognosis were identified, based on which a 12-gene signature was established for prognosis prediction. Multivariate Cox analysis suggested this signature was an independent predicting factor of overall survival (P < 0.001; HR:3.682; CI:2.377-5.705) and ROC curves indicated it has an effective predictive performance (1-year AUC: 0.653; 3-year AUC:0.673; 5-year AUC: 0.777). GSEA indicated that high risk score was correlated with several cancer-related pathways, including cytokine-cytokine receptor cross talk, ECM receptor cross talk, HEDGEHOG signaling cascade and JAK/STAT signaling cascade. ssGSEA analysis exhibited a significant correlation between immune status and the risk signature. Noscapine and clofazimine were screened as potential drugs for CRC patients with high-risk scores. TDRD5 and GPC1 were identified as hub genes and their expression were validated in 15 pairs of surgically resected CRC tissues.</p><p><strong>Conclusion: </strong>Our research provides a depth insight of RBPs' role in CRC and the proposed signature are helpful to the personalized treatment and prognostic judgement.</p>","PeriodicalId":12862,"journal":{"name":"Hereditas","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999506/pdf/","citationCount":"1","resultStr":"{\"title\":\"Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA.\",\"authors\":\"Lu Cao,&nbsp;Lili Duan,&nbsp;Rui Zhang,&nbsp;Wanli Yang,&nbsp;Ning Yang,&nbsp;Wenzhe Huang,&nbsp;Xuemin Chen,&nbsp;Nan Wang,&nbsp;Liaoran Niu,&nbsp;Wei Zhou,&nbsp;Junfeng Chen,&nbsp;Yiding Li,&nbsp;Yujie Zhang,&nbsp;Jinqiang Liu,&nbsp;Daiming Fan,&nbsp;Hong Liu\",\"doi\":\"10.1186/s41065-023-00274-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>RNA binding proteins (RBPs) have been implicated in oncogenesis and progression in various cancers. However, the potential value of RBPs as prognostic indicators and therapeutic targets in colorectal cancer (CRC) requires further investigation.</p><p><strong>Methods: </strong>Four thousand eighty two RBPs were collected from literature. The weighted gene co-expression network analysis (WGCNA) was performed to identify prognosis-related RBP gene modules based on the data attained from the TCGA cohorts. LASSO algorithm was conducted to establish a prognostic risk model, and the validity of the proposed model was confirmed by an independent GEO dataset. Functional enrichment analysis was performed to reveal the potential biological functions and pathways of the signature and to estimate tumor immune infiltration. Potential therapeutic compounds were inferred utilizing CMap database. Expressions of hub genes were further verified through the Human Protein Atlas (HPA) database and RT-qPCR.</p><p><strong>Results: </strong>One thousand seven hundred thirty four RBPs were differently expressed in CRC samples and 4 gene modules remarkably linked to the prognosis were identified, based on which a 12-gene signature was established for prognosis prediction. Multivariate Cox analysis suggested this signature was an independent predicting factor of overall survival (P < 0.001; HR:3.682; CI:2.377-5.705) and ROC curves indicated it has an effective predictive performance (1-year AUC: 0.653; 3-year AUC:0.673; 5-year AUC: 0.777). GSEA indicated that high risk score was correlated with several cancer-related pathways, including cytokine-cytokine receptor cross talk, ECM receptor cross talk, HEDGEHOG signaling cascade and JAK/STAT signaling cascade. ssGSEA analysis exhibited a significant correlation between immune status and the risk signature. Noscapine and clofazimine were screened as potential drugs for CRC patients with high-risk scores. TDRD5 and GPC1 were identified as hub genes and their expression were validated in 15 pairs of surgically resected CRC tissues.</p><p><strong>Conclusion: </strong>Our research provides a depth insight of RBPs' role in CRC and the proposed signature are helpful to the personalized treatment and prognostic judgement.</p>\",\"PeriodicalId\":12862,\"journal\":{\"name\":\"Hereditas\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999506/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hereditas\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1186/s41065-023-00274-z\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditas","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s41065-023-00274-z","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:RNA结合蛋白(rbp)参与多种癌症的发生和发展。然而,rbp作为结直肠癌(CRC)预后指标和治疗靶点的潜在价值需要进一步研究。方法:从文献中收集rbp 482例。采用加权基因共表达网络分析(WGCNA),根据TCGA队列获得的数据识别与预后相关的RBP基因模块。利用LASSO算法建立了预测风险模型,并通过独立GEO数据集验证了模型的有效性。功能富集分析揭示了该标记的潜在生物学功能和途径,并估计了肿瘤免疫浸润。利用CMap数据库推断潜在的治疗化合物。通过Human Protein Atlas (HPA)数据库和RT-qPCR进一步验证hub基因的表达。结果:在CRC样本中有1734个rbp存在差异表达,鉴定出4个与预后显著相关的基因模块,并以此为基础建立了预后预测的12个基因标记。多因素Cox分析提示rbp是总生存期的独立预测因素(P)。结论:我们的研究为rbp在结直肠癌中的作用提供了深入的认识,提出的rbp特征有助于个体化治疗和预后判断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA.

Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA.

Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA.

Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA.

Background: RNA binding proteins (RBPs) have been implicated in oncogenesis and progression in various cancers. However, the potential value of RBPs as prognostic indicators and therapeutic targets in colorectal cancer (CRC) requires further investigation.

Methods: Four thousand eighty two RBPs were collected from literature. The weighted gene co-expression network analysis (WGCNA) was performed to identify prognosis-related RBP gene modules based on the data attained from the TCGA cohorts. LASSO algorithm was conducted to establish a prognostic risk model, and the validity of the proposed model was confirmed by an independent GEO dataset. Functional enrichment analysis was performed to reveal the potential biological functions and pathways of the signature and to estimate tumor immune infiltration. Potential therapeutic compounds were inferred utilizing CMap database. Expressions of hub genes were further verified through the Human Protein Atlas (HPA) database and RT-qPCR.

Results: One thousand seven hundred thirty four RBPs were differently expressed in CRC samples and 4 gene modules remarkably linked to the prognosis were identified, based on which a 12-gene signature was established for prognosis prediction. Multivariate Cox analysis suggested this signature was an independent predicting factor of overall survival (P < 0.001; HR:3.682; CI:2.377-5.705) and ROC curves indicated it has an effective predictive performance (1-year AUC: 0.653; 3-year AUC:0.673; 5-year AUC: 0.777). GSEA indicated that high risk score was correlated with several cancer-related pathways, including cytokine-cytokine receptor cross talk, ECM receptor cross talk, HEDGEHOG signaling cascade and JAK/STAT signaling cascade. ssGSEA analysis exhibited a significant correlation between immune status and the risk signature. Noscapine and clofazimine were screened as potential drugs for CRC patients with high-risk scores. TDRD5 and GPC1 were identified as hub genes and their expression were validated in 15 pairs of surgically resected CRC tissues.

Conclusion: Our research provides a depth insight of RBPs' role in CRC and the proposed signature are helpful to the personalized treatment and prognostic judgement.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hereditas
Hereditas Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.80
自引率
3.70%
发文量
0
期刊介绍: For almost a century, Hereditas has published original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of genetics and genomics. Topics of interest include human and medical genetics, animal and plant genetics, microbial genetics, agriculture and bioinformatics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信